文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

《世界卫生组织造血与淋巴组织肿瘤分类》第五版:淋巴肿瘤。

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

机构信息

Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.

Department of Pathology, University of Miami, Miami, FL, USA.

出版信息

Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22.


DOI:10.1038/s41375-022-01620-2
PMID:35732829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9214472/
Abstract

We herein present an overview of the upcoming 5 edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4 edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5 edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

摘要

我们在此概述即将发布的第五版世界卫生组织血液淋巴肿瘤分类,重点介绍淋巴肿瘤。髓系和组织细胞肿瘤将在另一篇伴随文章中介绍。除了列出分类实体外,我们还强调并解释了与修订后的第四版相比的变化。这些变化包括通过在整个第五版世界卫生组织所有器官系统肿瘤分类中采用的层次系统对实体进行重组、对某些实体的命名进行修改、修改诊断标准或亚型、删除某些实体以及引入新实体,以及纳入肿瘤样病变、淋巴结和脾脏特有的间叶病变以及与淋巴肿瘤相关的种系易感性综合征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/6e38884e3243/41375_2022_1620_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/099599aae7ef/41375_2022_1620_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/f692c61d0344/41375_2022_1620_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/cf9985ce265e/41375_2022_1620_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/4ff504a29512/41375_2022_1620_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/8c8d5c876741/41375_2022_1620_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/69695336811e/41375_2022_1620_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/c065f217e21e/41375_2022_1620_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/6e38884e3243/41375_2022_1620_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/099599aae7ef/41375_2022_1620_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/f692c61d0344/41375_2022_1620_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/cf9985ce265e/41375_2022_1620_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/4ff504a29512/41375_2022_1620_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/8c8d5c876741/41375_2022_1620_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/69695336811e/41375_2022_1620_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/c065f217e21e/41375_2022_1620_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7225/9252901/6e38884e3243/41375_2022_1620_Fig8_HTML.jpg

相似文献

[1]
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Leukemia. 2022-7

[2]
The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors - an overview and update.

Leuk Lymphoma. 2024-4

[3]
What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?

J Hematop. 2024-6

[4]
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Leukemia. 2022-7

[5]
[Interpretation of lymphoid proliferations and lymphomas associated with immune deficiency and dysregulation in the 5th edition WHO classification of haematolymphoid tumours].

Zhonghua Bing Li Xue Za Zhi. 2024-7-8

[6]
[Interpretation of T-cell and NK-cell lymphoid proliferations and lymphomas in the 5th edition of the WHO classification of haematolymphoid tumours].

Zhonghua Bing Li Xue Za Zhi. 2024-6-8

[7]
Introduction to the Fifth Edition of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Mod Pathol. 2023-12

[8]
[WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors].

Arkh Patol. 2023

[9]
Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".

Arch Pathol Lab Med. 2021-5-1

[10]
Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes.

Mod Pathol. 2024-5

引用本文的文献

[1]
Prediction of double expression status of primary CNS lymphoma using multiparametric MRI radiomics combined with habitat radiomics: a double-center study.

J Neurooncol. 2025-9-9

[2]
Unicentric Castleman disease treated with rituximab before surgery: clinicopathologic findings.

Ann Hematol. 2025-9-6

[3]
Skin manifestations uncover underlying Follicular helper T-cell lymphoma, angioimmunoblastic-type in an immunosuppressed patient.

Virchows Arch. 2025-9-3

[4]
Chemokine Receptor Profiles as Predictors of Survival and Early Progression in Follicular Lymphoma.

EJHaem. 2025-8-28

[5]
Successful Treatment of Acquired von Willebrand Syndrome in a Rare Case of Nodal Marginal Zone Lymphoma With Rituximab Therapy: A Case Report.

Cureus. 2025-8-28

[6]
Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report.

Front Immunol. 2025-8-14

[7]
Multi-Cohort High-Dimensional Proteomics Reveals Early Risk Markers for Lymphoid Cancer Subtypes.

Res Sq. 2025-8-19

[8]
Primary Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma concurrent with lymphoepithelioma-like intrahepatic cholangiocarcinoma and cavernous hemangioma in liver.

Hepatobiliary Surg Nutr. 2025-8-1

[9]
Isolated bone marrow gamma/delta T-cell lymphoma: A difficult case to classify according to the current WHO classification of lymphoid malignancies.

Leuk Res Rep. 2025-8-8

[10]
Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.

Methods Mol Biol. 2025

本文引用的文献

[1]
Advances in the Treatment of Hairy Cell Leukemia Variant.

Curr Treat Options Oncol. 2022-1

[2]
Epstein-Barr virus positivity as a defining pathogenetic feature of Burkitt lymphoma subtypes.

Br J Haematol. 2022-2

[3]
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.

Am J Hematol. 2022-1-1

[4]
Whole-genome landscape of adult T-cell leukemia/lymphoma.

Blood. 2022-2-17

[5]
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.

Am J Hematol. 2021-12-1

[6]
Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.

Br J Haematol. 2022-2

[7]
Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma.

Nat Commun. 2021-9-22

[8]
Geographic Variability of Nodular Lymphocyte-Predominant Hodgkin Lymphoma.

Am J Clin Pathol. 2022-2-3

[9]
ALL is not the same in the era of genetics.

Blood. 2021-9-16

[10]
Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin.

Virchows Arch. 2022-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索